Idec (NASDAQ: BIIB) will present data supporting its approved
hemophilia therapies at the 56 th
Annual Meeting of the American Society of Hematology (ASH) taking
place in San Francisco, December 6-9.
for Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting investment picks